Brightsurf Science News and Current Science News Events
 
Email a Friend Send to a friend
Printer Friendly Print Double binding sites on tumor target may provide future combination therapy

Double binding sites on tumor target may provide future combination therapy

April 09, 2008

PHILADELPHIA - Researchers from the University of Pennsylvania School of Medicine and colleagues at Merck Serono Research in Germany have found that two drugs bind to receptor sites on some tumors in different places at the same time, suggesting the possibility of a new combination therapy for certain types of cancer.

An increasing number of therapies targeting tumors that have proteins called epidermal growth factor receptors (EGFR) sitting on their surface are already being used in the clinic or are in late stages of development. For example, Herceptin is an established treatment for certain types of breast cancer and Erbitux and Vectibix are in use for other types of cancer. An additional drug called matuzumab is in phase II clinical trials.




Three years ago, Kate Ferguson, PhD, Assistant Professor of Physiology, and colleagues determined the precise molecular details of how Erbitux, a colorectal and head and neck cancer drug, binds to its target on cancer cells. EGFR drugs halt cell proliferation by blocking EGFR's molecular doorway, keeping hormones from binding and signaling tumor growth. X-ray crystallography provided a snapshot of the interaction between Erbitux and the extracellular component of the cancer cell's receptors.

As is characteristic of many epithelial cancers - such as cancers of the colon, head and neck, breast, ovary, lung, and pancreas - the surface of cancer cells possess abnormally high levels of EGFR. In a cancer cell, an extracellular hormone binds to the outer piece of EGFR, and causes the inside part to kick off a series of reactions that signal the cancerous cell to replicate and divide.

In the present study, published in Cancer Cell, Ferguson and Merck colleagues found - again using X-ray crystallography -- that matuzumab binds in a different place from Erbitux. Their binding does not overlap, and they can bind to EGFR at the same time.

"These findings imply that a combination therapy using both types of EGFR drugs could be developed and tested," says Ferguson. "This has important implications for the clinical use of matuzumab and for developing new therapies that target EGFR."

University of Pennsylvania School of Medicine



Related Combination Therapy News Articles Combination Therapy News and Current Combination Therapy Events RSS Combination Therapy News and Current Combination Therapy Events RSS
Anti-tumor effects are enhanced by inhibiting 2 pathways rather than 1
Two independent research groups have found that simultaneous inhibition of two signaling pathways resulted in substantially enhanced antitumor effects in mouse models of prostate and breast cancer. In an accompany commentary, Steven Grant, at Virginia Commonwealth University Health Science Center, Richmond, discusses the clinical importance of these studies and highlights some of the questions that still need to be answered.

Experimental chemotherapy regimen shows promise in treating advanced lung cancer
A combination of chemotherapy agents that have been tested in other tumor types appears to be a promising alternative to standard treatment for advanced non-small cell lung cancer, according to a report in the August 15 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.

New Cancer Treatment Targets Both Tumor Cells and Blood Vessels
It takes more than one punch to fight tumors. Often, tumors have more than one way of surviving, and attacking the tumor alone is not enough.

Experimental anti-cancer synthetic molecule targets tumor cell growth and angiogenesis
A recent study conducted by three French CNRS (Centre National de la Recherche Scientifique) laboratories describes a new candidate anti-cancer drug, named HB-19.

Cancer-killing viruses influence tumor blood-vessel growth
Viruses genetically designed to kill cancer cells offer a promising strategy for treating incurable brain tumors such as glioblastoma, but the body's natural defenses often eliminate the viruses before they can eliminate the tumor.

New patient satisfaction study with budesonide/formoterol combination therapy
A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy.

CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients
New data show that CAPHOSOL® (www.caphosol.com), an advanced electrolyte solution, relieves painful oral mucositis (OM) and improves quality of life for cancer patients undergoing chemotherapy and radiation therapy.

New agent strikes at respiratory syncytial virus replication
University of Texas Medical Branch at Galveston researchers have achieved promising results with a potential new weapon against respiratory syncytial virus, the most common cause of infant hospitalization in the United States.

Study shows positive findings in treating patients with advanced hepatitis C
The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).

International health experts to enlist the public in war on African malaria
Philanthropy just got easier and a lot more accessible to the public thanks to the social networking power of the Internet and a ground-breaking partnership between a young British entrepreneur, a global health think tank and an African medical research institute.
More Combination Therapy News Articles


Food Synergy: Unleash Hundreds of Powerful Healing Food Combinations to Fight Disease and Live Well
by Elaine Magee

Over the past few years, scientists have made dramatic new breakthroughs in harnessing the healing power of foods. In addition to discovering which "superfoods" offer maximum health benefits, they now know that some nutrients pack a special healing wallop when eaten together rather than alone. In more than 25 books and her nationally syndicated newspaper column "The Recipe Doctor," popular food...



Type 2 Diabetes Mellitus:: An Evidence-Based Approach to Practical Management (Contemporary Endocrinology)

As the global epidemic of diabetes continues to expand, the prevalence of type 2 diabetes is predicted to double in the next 20 years. Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management addresses this problem by expertly synthesizing the currently available evidence regarding specific issues in diabetes care. Written by an interdisciplinary team of scientists and medical...

Drug combination shows efficacy in psychotic depression.(Adult Psychiatry): An article from: Clinical Psychiatry News
by Sherry Boschert

This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on July 1, 2005. The length of the article is 522 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Drug...



Targeted Cancer Therapy (Current Clinical Oncology) (Current Clinical Oncology)

Emerging technologies in target identification, drug discovery, molecular markers, and imaging are rapidly changing the face of cancer. Targeted Cancer Therapy provides a foundation of knowledge in targeted cancer therapeutics. The treatment of cancer is increasingly being individualized, based on an understanding of underlying biologic mechanisms. Poised to change the landscape in oncology,...

Renal artery stenosis reversal in a hypertensive individual, using a combination of EDTA chelation and multiple vitamin and trace mineral therapy.(Disease/Disorder ... : An article from: Original Internist
by C.J. Rudolph, E.W. McDonagh

This digital document is an article from Original Internist, published by Thomson Gale on March 22, 2006. The length of the article is 2567 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Renal...



Antiepileptic Drugs: Combination Therapy and Interactions

This book reviews the use of antiepileptic drugs focusing on the interactions between these drugs and between antiepileptics and other drugs. These interactions can be beneficial or can cause harm. The aim of this book is to increase awareness of the possible impact of combination pharmacotherapies. Pharmacokinetic and pharmacodynamic interactions are discussed supported by clinical and...

A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence *.: An article from: Journal of Studies on Alcohol
by Helen M. Pettinati, Roger D. Weiss, William Dundon, William R. Miller, Dennis Donovan, Denise B. Ernst, Bruce J. Rounsaville

This digital document is an article from Journal of Studies on Alcohol, published by Thomson Gale on July 1, 2005. The length of the article is 7017 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.From the author: ...

Drug-induced parkinsonism often missed by experts: the older, conventional antipsychotic drugs have been most commonly associated with the problem.(care ... An article from: Clinical Psychiatry News
by Kerri Wachter

This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on April 1, 2006. The length of the article is 844 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...



Combination Therapy for Asthma and Chronic Obstructive Pulmonary Disease (Lung Biology in Health and Disease, V. 145)

This book examines the therapies used for treatment of asthma and chronic obstructive pulmonary disease (COPD) separately and in combination, covering beta-agonists, theophylline, leukotriene modifiers, and anticholinergics. Highlights the importance of specific time dosing of medications! Revealing what medications to use and when to prescribe them, Combination Therapy for Asthma and Chronic...

Q-switched Alexandrite laser-assisted treatment of melasma: 2-year follow-up monitoring.(CASE REPORTS): An article from: Journal of Drugs in Dermatology
by Antonio Rusciani, Angela Motta, Luigi Rusciani, Carmine Alfano

This digital document is an article from Journal of Drugs in Dermatology, published by Thomson Gale on November 1, 2005. The length of the article is 2043 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

© 2008 BrightSurf.com